Cytokinetics financials

Author: vxit

August undefined, 2024

WebJun 27, 2024 · Financials CYTK has a market cap of $4.05bn and a cash balance of $686mn. Research and development expenses for the first quarter 2024 were $45.9 million, while general and administrative... WebApr 13, 2024 · The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity. Cytokinetics' US$34.05 share price indicates it is trading at similar levels as its fair value estimate

Cytokinetics To Participate In The 22nd Annual Needham Virtual ...

WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential … Web12 hours ago · In a report released yesterday, Madhu Kumar from Goldman Sachs maintained a Buy rating on Cytokinetics. The company’s shares closed last Thursday at … pony dick colliery working plans

Cytokinetics Reports Third Quarter 2024 Financial Results

WebApr 2, 2024 · Financials In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same … WebOperating Status Active. Last Funding Type Post-IPO Debt. Legal Name Cytokinetics, Inc. Stock Symbol NASDAQ:CYTK. Company Type For Profit. Contact Email [email protected]. Phone Number 6506243010. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and … WebApr 12, 2024 · Finally, Truist Financial assumed coverage on Cytokinetics in a report on Tuesday, December 20th. They issued a “buy” rating and a $60.00 price target for the company. One research analyst has ... pony dining review

Estimating The Fair Value Of Cytokinetics, Incorporated ... - Yahoo Finance

CYTK Stock Price Cytokinetics Inc. Stock Quote (U.S.: Nasdaq ...

WebMay 6, 2024 · SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $47.1 million, or $0.66 per share, compared to net loss for the first quarter of 2024 of $39.4 million, or $0.66 per share. WebCYTK Finanicals Stock Screener Earnings Calendar Sectors Nasdaq CYTK U.S.: Nasdaq Cytokinetics Inc. Watch list Create CYTK Alert After Hours Last Updated: Mar 8, 2024 … pony dive bottleWebApr 10, 2024 · Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which ... pony dive tank and back pack

"WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated ( Nasdaq: CYTK) today announced that Robert I. Blum, … " - Cytokinetics financials

Cytokinetics financials

CYTK - Cytokinetics Inc Stock quote - CNNMoney.com

WebApr 11, 2024 · Cytokinetics, Incorporated (CYTK) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 33.36 -0.27 (-0.80%) At close: 04:00PM EDT 33.36 0.00 (0.00%) After hours: 04:11PM EDT Time... WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2024. Net loss for the fourth quarter was $137.4 millionor $1.45per share and the net loss for the year 2024 was $389.0 millionor $4.33per share.

Did you know?

WebDescription. Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle …

WebFeb 17, 2024 · Cytokinetics Financials Summary financials Revenue ( FY, 2024) $94.6M Net income ( FY, 2024) ($389.0M) Cash ( FY, 2024) $65.6M EBIT ( FY, 2024) ($324.2M) … WebCytokinetics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View CYTK financial statements in full.

WebAug 4, 2024 · SOUTH SAN FRANCISCO, Calif., Aug. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2024. Net loss for the second... WebApr 10, 2024 · Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the …

WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth …

WebNov 3, 2024 · Enrollment Complete in Cohort 3 of REDWOOD-HCM; Results Expected in Q1 2024. SOUTH SAN FRANCISCO, Calif., Nov. 03, 2024 (GLOBE NEWSWIRE) -- … pony dictionaryWebApr 6, 2024 · Cytokinetics Inc. detailed financials by Barron's. View CYTK business summary and company performance, for a clear financial breakdown. pony distressed sideboardWeb18 hours ago · Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 04/03/23-4:00PM EST GlobeNewswire 3 Best Stocks to Buy Now, 4/3/2024, According to Top Analysts shapeoko hdm specsWebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 … pony diseasesWebAug 5, 2024 · SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2024. ... Financials. Revenues for the ... shapeoko waste board fileWebFeb 24, 2024 · Cytokinetics has received committed capital of $70 million, and will receive up to $330 million from Ji Xing in additional milestone payments plus tiered royalties on the net sales of omecamtiv mecarbil in Greater China, subject to certain reductions. 2024 … shapeoko mc etcherWebMar 24, 2024 · CYTOKINETICS, INCORPORATED : Forcasts, revenue, earnings, analysts expectations, ratios for CYTOKINETICS, INCORPORATED Stock CYTK US23282W6057 shapeoko post processor fusion 360